Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab
or panitumumab, are widely used targeted therapeutics for the treatment of patients with …

Aim: The aim of the study was to assess the degree to which tissue polypeptide antigen (TPA)
and tissue polypeptide-specific antigen (TPS), as well as carcinoembryonic antigen (CEA), …

Aim: The first aim of this study was to search for new biomarkers to be used in gastric cancer
diagnostics. The second aim was to verify the findings presented in literature on a sample of …

Objective To describe the incidence of febrile neutropenia (FN) and use of pegfilgrastim in
cancer patients with high overall risk of FN and to investigate the relationship between …

Purpose In the integrated analysis of phase III head-to-head trials in patients with advanced
solid tumors, denosumab demonstrated superiority over zoledronic acid in preventing …

Background.–Trastuzumab is known as an active agent in HER2/neu overexpressing
advanced breast cancer. In the prospective study we investigated efficacy, safety and toxicity of …

Febrile neutropenia (FN) is a common and potentially fatal complication of anticancer treatment,
particularly in patients receiving myelosuppressive chemotherapy. It has been shown …

Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab
are regimens used in combination with checkpoint inhibitors in non-squamous non-small …

Purpose. Trastuzumab is known as an active agent in HER2/neu overexpressing metastatic
breast cancer. In the prospective study we investigated efficacy, safety and toxicity of …

Aims and objectives: In real-life practice, a proportion of lung adenocarcinoma patients exists
with good response to most of the administered drugs, resulting in favourable outcomes. …